Skip to main content
SpringerLink
Log in

Pharmacologic Treatments for Addiction

  • Chapter
  • First Online:
Perioperative Addiction

  • 955 Accesses

Abstract

Prescription drug abuse, especially the illegal use of opiates such as Oxycontin®, has reached epidemic proportions in the United States. Patients who are opiate dependent can be very challenging to care for. Chronic opiate use significantly alters neurophysiology and limits the effectiveness of many anesthetic medications. Similarly, many of the agents now used to attempt to detoxify patients may also alter anesthetic responsiveness. A detailed knowledge of the pharmacology of the agents used to maintain and detoxify addicts is essential for successful perioperative management of these challenging patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother. 2002;36:312–21.

    Article  PubMed  CAS  Google Scholar 

  2. Ling W. Buprenorphine for opioid dependence. Expert Rev Neurother. 2009;9(5):609–16.

    Article  PubMed  CAS  Google Scholar 

  3. National Survey on Drug Use and Health, 2005. Rockville, MD, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. 2006. Available at www.icpsr.umich.edu/cocoon/ICPSR/STUDY/04596.xml.

  4. The Determinations Report: A Report on the Physician Waiver Program Established by the Drug Addiction Treatment Act of 2000 (“DATA”). Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment; 2006.

    Google Scholar 

  5. Patient Brochure. Suboxone Facts for Patients. Richmond, VA: Reckitt Benckiser Pharmaceuticals Inc; 2008. p. 23235.

    Google Scholar 

  6. Orman JS, Keating GM. Buprenorphine/Naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009;69(5):577–607.

    Article  PubMed  CAS  Google Scholar 

  7. Johnson RE, Jones HE, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate. Drug Alcohol Depend. 2003;70 Suppl 1:S87–101.

    Article  PubMed  CAS  Google Scholar 

  8. Michel E, Zernikow B. Buprenorphine in children. A clinical and pharmacological review. Schmerz. 2006;20:40–50.

    Article  PubMed  CAS  Google Scholar 

  9. Geib AJ, Babu K, Burns M, et al. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics. 2006;118:1746–51.

    Article  PubMed  Google Scholar 

  10. Hand CW, Sear JW, Uppington J. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth. 1990;64:276–82.

    Article  PubMed  CAS  Google Scholar 

  11. Berson A, Gervais A, Cazals D, et al. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol. 2001;34:346–50.

    Article  PubMed  CAS  Google Scholar 

  12. Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict. 2000;9:265–9.

    Article  PubMed  CAS  Google Scholar 

  13. Jones HE, Johnson RE, Milio L. Post-cesarean pain management of patients maintained on methadone or buprenorphine. Am J Addict. 2006;15(3):258–9.

    Article  PubMed  Google Scholar 

  14. Book SW, Myrick H, Malcolm R, Strain EC. Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient. Am J Psychiatry. 2007;164:979.

    Article  PubMed  Google Scholar 

  15. Alford DP, Compton P, Samet JH. Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med. 2006;144(2):127–34.

    PubMed  CAS  Google Scholar 

  16. Robert DM, Meyer-Witting M. High-dose buprenorphine: perioperative precautions and management strategies. Anaesth Intensive Care. 2005;33:17–25.

    Google Scholar 

  17. Schuh KJ, Walsh SL, Stitzerr ML. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology. 1999;145:162–74.

    Article  PubMed  CAS  Google Scholar 

  18. Welsh C, Sherman SG, Tobin KE. A case of heroin overdose reversed by sublingually administered buprenorphine/naloxone (Suboxone®). Addiction. 2008;103:1226–8.

    Article  PubMed  Google Scholar 

  19. Totah R, Sheffels P, Robert T, et al. Role of CYP2B6 in steroselective human methadone metabolism. Anesthesiology. 2008;108:363–74.

    Article  PubMed  CAS  Google Scholar 

  20. Mahajan G, Fishman SM. Opioids in Pain Management. In: Benzon HT, editor. Essentials of pain medicine and regional anesthesia. 2nd ed. Philadelphia, PA: Elsevier; 2005. Major Chapter 11.

    Google Scholar 

  21. Sims SA, Snow LA, Porucznik CA. Surveillance of Methadone related adverse drug events using multiple public health data sources. J Biomed Inform. 2007;40:382–9.

    Article  PubMed  Google Scholar 

  22. Glajchen M. Chronic pain: treatment barriers and strategies for clinical practice. J Am Board Fam Pract. 2001;14:211–8.

    PubMed  CAS  Google Scholar 

  23. Zanger UM, Klein K, Saussele T. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics. 2007;8:743–59.

    Article  PubMed  CAS  Google Scholar 

  24. Peng PW, Tumber PS, Gourley D. Review article: perioperative pain management of patients on methadone therapy. Can J Anaesth. 2005;525:513–23.

    Google Scholar 

  25. Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234–42.

    Article  PubMed  CAS  Google Scholar 

  26. Mash DC, Kovera CA, Pablo J, et al. Ibogaine in the treatment of heroin withdrawal. Alkaloids. 2001;56:155–71.

    Article  PubMed  CAS  Google Scholar 

  27. Hoelen DW, Spiering W, Valk GD. Long-QT syndrome induced by the antiaddiction drug ibogaine. N Engl J Med. 2009;360(3):308–9.

    Article  PubMed  CAS  Google Scholar 

  28. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9–24.

    Article  PubMed  CAS  Google Scholar 

  29. Mattick RP, Breen C, Kinbler J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;8(3):CD002209.

    Google Scholar 

  30. Kaye AD, Banister RE, Hoover JM, et al. Chronic pain and ultra rapid opioid detoxification. Pain Physician. 2005;5(1):33–42.

    Google Scholar 

  31. Shader RI. Antagonists, inverse agonists, and protagonists. J Clin Psychopharmacol. 2003;23(4):321–2.

    Article  PubMed  Google Scholar 

  32. Therapeutic Goods Administration. “Australian Register of Therapeutic Goods Medicines” (Online database of approved medicines). https://www.ebs.tga.gov.au/ebs/ANZTPAR/PublicWeb.nsf/cuMedicines?OpenView. Accessed 11 May 2010.

  33. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust. 2002;176(11):530–4.

    PubMed  Google Scholar 

  34. Heinälä P et al. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind placebo-controlled trial. J Clin Psychopharmacol. 2001;21:287–92.

    Article  PubMed  Google Scholar 

  35. O’Malley SS, Jaffe A, Chang G, Witte R, et al. Naltrexone in the treatment of alcohol dependence. In: Reid LD, editor. Opioids, bulimia, and alcohol abuse and alcoholism. New York, NY: Springer; 1990.

    Google Scholar 

  36. National Institutes of Health. Naltrexone or specialized alcohol counseling an effective treatment for alcohol dependence when delivered with medical management. Press release; May 2, 2006.

    Google Scholar 

  37. Sinclair JD. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol. 2001;36(1):2–10.

    PubMed  CAS  Google Scholar 

  38. Schmitz J, Stotts A, Rhoades H, Grabowski J. Naltrexone and relapse prevention treatment for cocaine-dependent patients. Addict Behav. 2001;26(2):167–80.

    Article  PubMed  CAS  Google Scholar 

  39. Anton R, Oroszi G, O’Malley S, et al. An evaluation of opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence. Arch Gen Psychiatry. 2008;65(2):135–44.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Somnia Pain Management, New Rochelle, NY, USA

    Clifford Gevirtz MD, MPH

  2. Department of Anesthesiology and Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA

    Ethan O. Bryson MD

  3. Department of Anesthesiology, Mount Sinai School of Medicine, New York, NY, USA

    Elizabeth A. M. Frost MBChB, DRCOG

Authors
  1. Clifford Gevirtz MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ethan O. Bryson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elizabeth A. M. Frost MBChB, DRCOG
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Clifford Gevirtz MD, MPH .

Editor information

Editors and Affiliations

  1. Department of Anesthesiology, Mount Sinai School of Medicine, Associate Professor, New York, 10029, New York, USA

    Ethan O. Bryson

  2. Department of Anesthesiology, Mount Sinai School of Medicine, Professor, New York, 10029, New York, USA

    Elizabeth A. M. Frost

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gevirtz, C., Bryson, E.O., Frost, E.A.M. (2012). Pharmacologic Treatments for Addiction. In: Bryson, E., Frost, E. (eds) Perioperative Addiction. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-0170-4_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-0170-4_3

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-0169-8

  • Online ISBN: 978-1-4614-0170-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation